GSL: General Sales Licence
This information is intended for use by health professionals
Lemsip Cough for Chesty Cough 50mg/5ml Oral Solution
Sucrose: 3.965 g per 5ml dose
Sodium: 3.66 mg (0.16mmol) per 5ml dose
For full list of excipients, see section 6.1 .
Symptomatic relief of deep chesty coughs and to soothe the throat.
For oral administration.
Under 12 years: On medical advice only
To be taken three or four times daily.
Adults and children 12 years and over: two to four 5ml spoonfuls.
PETE plastic bottle
Adults and children 12 years and over: 10 ml dose (fill measure cup to 10 ml); 15 ml (one 10 ml measure in cup followed by a 5 ml measure); 20 ml (10 ml taken twice). Rinse the measure cup after use.
Hypersensitivity to guaifenesin or to any of the excipients.
This medicine contains 0.16 mmol (or 3.66 mg) sodium per 5 ml dose. To be taken into consideration by patients on a controlled sodium diet.
Contains 3.965 g of sucrose per 5 ml dose. This should be taken into account in patients with diabetes mellitus.
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
If urine is collected within 24 hours of a dose of the medicinal product, a metabolite of guaifenesin may cause a colour interference with laboratory determinations of urinary 5-hydroxyindoleacetic acid (5-HIAA) and vanillylmandelic acid (VMA).
Guaifenesin may increase the rate of absorption of paracetamol.
Guaifenesin has been linked with an increased risk of neural tube defects in a small number of women with febrile illness in the first trimester of pregnancy. The product should be used in pregnancy only if the benefits outweigh this risk. There is no information on use in lactation.
Guaifenesin has occasionally been reported to cause gastro-intestinal discomfort, nausea and vomiting, particularly in very high doses. Also, hypersensitivity reactions may occur.
Very large doses may cause nausea and vomiting. The drug is, however, rapidly metabolised and excreted in the urine. Patients should be kept under observation and treated symptomatically.
Guaifenesin is reported to reduce the viscosity of tenacious sputum and is used as an expectorant.
The active ingredient is not known to cause sedation.
Guaiphenesin is absorbed from the gastrointestinal tract. It is metabolised and excreted in the urine.
No preclinical findings of relevance to the prescriber have been reported.
Citric acid anhydrous granular,
Lemon oil terpeneless,
Glass bottle - Three years.
Transparent blue plastic PETE bottle - Two years.
Transparent green plastic PETE bottle - Two years.
Amber glass bottles with a polypropylene cap with a child resistant closure with a polyethylene tamper-evident band with expanded polyethylene wad (100ml, 150 ml, 200ml and 300 ml).
Transparent blue plastic PETE bottle (180 ml).
Transparent green plastic PETE bottle (180ml).
Translucent yellow graduated polypropylene measuring cup.
Pack size: 100 ml, 150 ml, 180ml, 200 ml and 300 ml.
To be taken orally at the recommended dose.
Reckitt Benckiser Healthcare (UK) Limited
RB Consumer Relations, PO Box 4644, SLOUGH, SL1 0NS, UK
0333 2005 345
0333 2005 345
0333 2005 345